ReviewPharmaceutics2025

Strategic Combinations of Antibody-Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens.

Heewon Jang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.